Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma.
10.3349/ymj.2011.52.1.196
- Author:
Won Seop LEE
1
;
Dae Hyeok KIM
;
Sung Hee SHIN
;
Seoung Il WOO
;
Jun KWAN
;
Keum Soo PARK
;
Sang Don PARK
;
Hyeon Gyu YI
;
Sang Hoon JEON
Author Information
1. Department of Internal Medicine, Inha University College of Medicine, Incheon, Korea. kdhmd@inha.ac.kr
- Publication Type:Case Report
- Keywords:
Bortezomib;
multiple myeloma;
adverse effect;
atrioventricular block
- MeSH:
Atrioventricular Block/*chemically induced;
Boronic Acids/*adverse effects/*therapeutic use;
Female;
Humans;
Middle Aged;
Multiple Myeloma/*drug therapy;
Pyrazines/*adverse effects/*therapeutic use
- From:Yonsei Medical Journal
2011;52(1):196-198
- CountryRepublic of Korea
- Language:English
-
Abstract:
Bortezomib is an inhibitor of 26S proteasome, which is an effective treatment for multiple myeloma. The common adverse effects of bortezomib are asthenic conditions, gastrointestinal disturbances, and peripheral neuropathy. Here we describe a patient with dyspnea and general weakness because of complete atrioventricular block while receiving bortezomib. We immediately stopped bortezomib, and after inserting a permanent VDD pacemaker, the patients' symptoms disappeared.
